Research - Página 7 de 10 - Fideres

Are Options Investors Adequately Compensated in Securities Litigation?

Key Points Class definition in securities fraud claims is often restricted to shares, neglecting the holders of options who are

febrero 18, 2019

Pay-to-Delay: Biosimilars and the Cost of Competition

Key Points Biosimilar drugs are non-generic alternatives to traditional biologic medicines, that sell at a fraction of the price. Scrutiny

Patisserie Valerie’s Bitter Aftertaste: A Forensic Accounting Tale

Key Points The holding company of UK café chain Patisserie Valerie is facing financial turmoil after discovering significant and potentially fraudulent

noviembre 28, 2018

Europe’s Truck Cartel: Collusion on the Road

Key Points European Commission decisions of 2016 and 2017 found six European truck manufacturers guilty of price-fixing for a 14-year

septiembre 3, 2018

The Hidden Cost of No-Poach Agreements

Key Points Fideres’s investigation found preliminary economic evidence to suggest widespread wage suppression in occupations within the healthcare and fast-food

septiembre 3, 2018

Dream Sold, Reality Bit: The Mis-Selling of Financial Hedging Products

Key Points Fideres shows that commercial borrowers may have significantly overpaid on interest payments as a result of banks selling

Municipal Bonds: Low Yields, High Questions

Key Points Fideres finds that underwriters systematically misprice US municipal bonds (“Muni Bonds”). We estimate that, between 2006 and 2015,

Structured Ratings: Credit Agencies Revisited

Key Points It is generally accepted that rating agencies did a poor job rating structured credit products in the years

Passing The Buck: When Damages End Up Elsewhere

Key Points Fideres explores the available economic methods used to estimate pass-on damages. We present two approaches that avoid common

diciembre 8, 2017